Analysts have modestly reduced their price targets for QuidelOrtho to $40.33, reflecting a cautious outlook despite solid quarterly results and prudent guidance, as the market awaits further proof of sustainable performance.
Analyst Commentary
- Revenues for the quarter were roughly in line with estimates, with Labs outperforming expectations and respiratory revenues meeting expectations.
- The quarter was described as strong and "fairly clean" by analysts.
- Updated company guidance is seen as prudent due to the market's "show me" attitude regarding future performance.
- Planned cost actions for the second half of 2025 are viewed positively for their potential to improve financials.
- Price target reductions reflect cautious sentiment despite operational positives, with continued Buy/Outperform ratings indicating some underlying confidence.
What's in the News
- Launched QUICKVUE Influenza + SARS Test, a rapid, visually read combo test for differentiating influenza A/B and COVID-19 at the point of care, expanding the QUICKVUE portfolio and reinforcing leadership in respiratory diagnostics.
- Introduced a Certified Analyzer Program to improve access to VITROS analyzers and diagnostics for rural and small hospitals, aiming to enhance quality and affordability in underserved communities.
- Announced availability of BUHLMANN fCAL turbo and fPELA turbo assays on VITROS Systems for improved, non-invasive gastrointestinal and pancreatic health diagnostics, featuring rapid results and simplified workflows.
- Reiterated full-year 2025 revenue guidance of $2.60–$2.81 billion.
- Added to multiple Russell growth and value benchmarks (e.g., Russell 2500 Growth, 3000 Growth, 2000 Value), while dropped from Russell Midcap Value and 1000 Value benchmarks.
Valuation Changes
Summary of Valuation Changes for QuidelOrtho
- The Consensus Analyst Price Target has fallen from $43.43 to $40.33.
- The Future P/E for QuidelOrtho has fallen from 237.30x to 219.23x.
- The Discount Rate for QuidelOrtho remained effectively unchanged, moving only marginally from 10.75% to 10.56%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.